There's a new challenger to the more established players in the weight-loss drug space.

Wall Street’s major market averages ended lower on Friday as tech stocks fell and U.S. Treasury yields marched higher following the U.S.-China summit ending. Wall Street had a slew of upgrades and ...

This clinical-stage biotech develops bifunctional antibody therapies targeting solid tumors for oncology providers and ...

Chandan Taparia has recommended three stocks to buy today, 15 May 2026 - National Aluminium Company, Apollo Hospitals ...

Top 10 mid-cap stocks by YTD performance amid market volatility—see 600%+ gainers across semis, biotech & more, plus mid-cap ...

Stifel upgrades RXO to buy from hold Stifel said its sees "idiosyncratic levers" for the asset-light transportation company. ...

It's no longer a secret that the Teva Pharmaceutical Industries (NYSE: TEVA) of the past is no more. The Israel-based company ...

Get all latest & breaking news on Cello World. Watch videos, top stories and articles on Cello World at moneycontrol.com.

Top picks include a consensus buy on NMDC, alongside Zydus Lifesciences, Varun Beverages (VBL), Max Healthcare, and Tata ...

ICICI Direct maintained a 'Buy' rating with a target price of Rs 5,750. The firm highlighted that revenues grew, driven by established power brands such as Eliquis, Magnex, and Meronem.

Novo Nordisk and Biogen are underpriced and stand to gain from new indications for their blockbuster therapies.

The ASX healthcare sector has fallen for the week ending May 15, 2026 as the sector's largest stock CSL tumbles on full year FY26 outlook.